louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06739863: Evaluation of Healthcare Waste Management Practices and Problems Among Primary and Secondary Hospitals
Official title: Evaluation of Different Healthcare Waste Management Practices and Problems Among Primary and Secondary Hospitals in Mianwali
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Healthcare Associated Infection
Lead sponsor: Superior University
Sponsor class: OTHER
First posted: 2024-12-18
Enrollment: 112
Sex: ALL
Minimum age (years): 25
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: included heathcare workers in hospitals including Operation theatre Staff, intensive care staff and labour room staff and laboratory room staff will be included, Doctors, Nurses, Nursing assistants, OT Technician, Maid's helpers, and sanitary workers

Brief summary: Healthcare waste is defined as the total waste stream from a healthcare facility. Most of it (75-90%) is similar waste to domestic waste and is known as healthcare general waste and is made up of paper, plastic packaging, food preparation etc. But as a similar proportion (10-25%) is hazards waste and requires special treatment. If these two categories of wastes are not separated properly then the entire volume of healthcare waste is considered as infectious and hazardous to human health and can result in disease and injury so it is necessary to set up a safe and integrated management system.

In this cross-sectional study public hospitals of Mianwali City will be selected by simple random sampling for observation of practices of hospital waste management.

Detailed description: The data will be collected through structured Questionnaire and possibly on-sit Quantitative data on waste management practices, types of waste, compliance with regulations, and perceived challenges.

Eligibility criteria: Inclusion Criteria:

* Operation theatre Staff
* intensive care staff and labour room staff and laboratory room staff will be included.
* Doctors, Nurses, Nursing assistants, OT Technician, Maid's helpers, and sanitary workers.

Exclusion Criteria:

* Management staff will be excluded.

Primary outcomes:
measure: T.Test
timeFrame: 12 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Miānwāli
country: Pakistan
facility: all Shumali Tehsil piplan District Mianwali
state: Punjab
Study officials:
References:
Clinical trial NCT06101563: Duration Between Drainage and Ureteroscopic Lithotripsy
Official title: Optimal Duration Between Drainage for Obstructing Renal or Ureteral Stones Associated With Infection and Ureteroscopic Lithotripsy: A Randomized Controlled Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Ureter Stone
Renal Stone
Ureteric Obstruction
Keywords: Ureteroscopy
Sepsis
infectious complications
ureteric calculi
Renal calculi
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2023-10-26
Enrollment: 96
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will be conducted to compare early (seven days) versus delayed (14-21 days) definitive ureteroscopic lithotripsy after initial drainage for obstructing ureteral or renal stones associated with infection.

Detailed description: All the study participants will be monitored during the early post-operative period for post-operative pain and complications. The rate and grade of reported complications will be determined according to modified Dindo-Clavian grading system. After ensuring safe status for discharge, all patients will be reassessed at the outpatient department after 4 weeks by NCCT to assess stone free status.

Eligibility criteria: Inclusion Criteria:

1. Obstructing ureteral or renal stone \<20 mm.
2. Associated clinical evidence of acute upper urinary tract infection based on systemic inflammatory response syndrome (SIRS).

Exclusion Criteria:

1. History of endoscopic instrumentation to the urinary tract in the last 4 weeks prior to presentation.
2. Bilateral obstructed kidneys necessitating bilateral drainage.
3. Associated emphysematous pyelonephritis or perinephric abscess.

Primary outcomes:
measure: Percentage of postoperative infectious complications in treatment groups
timeFrame: 30 days
Secondary outcomes:
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Urology and Nephrology Center
Study officials:
affiliation: Professor
name: Yaser Osman, MD
role: STUDY_CHAIR
affiliation: Lecturer
name: Mahmoud Laymon, MD,MRCS
role: STUDY_CHAIR
References:
Clinical trial NCT00261963: The Effect of UV-Irradiation on Cutaneous Cicatrices
Official title: The Effect of UV-Irradiation on Cutaneous Cicatrices -A Randomised, Controlled Study With Clinical, Skin Reflectance, Histological and Biochemical Evaluations
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Skin Cicatrices
Lead sponsor: Bispebjerg Hospital
Sponsor class: OTHER
First posted: 2005-12-06
Enrollment: 15
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to examine the effect of UV-irradiation on human cutaneous cicatrices by clinical examinations and histological, immunohistochemical and biochemical analyses.


Eligibility criteria: Inclusion Criteria:

* Non-smoking volunteers,
* Skintypes II or III

Exclusion Criteria:

* Atopic dermatitis,
* Tendency to produce keloids or hypertrophic scars,
* Exposure of UV light during the last 3 months,
* Medical treatment

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Bispebjerg Hospital
state: Copenhagen NV
Study officials:
affiliation: Bispebjerg Hospital
name: Eva Due, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02603263: The Effect of a Descriptive Norm Promoting Vegetable Selection in a Workplace Restaurant Setting: an Observational Study
Official title: The Effect of a Descriptive Norm Promoting Vegetable Selection in a Workplace
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Eating Behaviour
Keywords: social norms
healthy eating
vegetables
field study
Lead sponsor: University of Birmingham
Sponsor class: OTHER
Collaborators: name: Economic and Social Research Council, United Kingdom
name: C H & Co Ltd.
First posted: 2015-11-11
Enrollment: 9445
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Customers at workplace restaurants.

Brief summary: Encouraging individuals to eat fruit and vegetables is difficult. However, recent evidence suggests that using social-based information might help. For instance, it has been shown that if people think that others are eating lots of fruit and vegetables, that they will consume more food to match the 'norm'.The purpose of this study was to determine whether social norm messages could be used to enhance vegetable purchases in workplace restaurants, in an observational study.

Detailed description: In this study the investigators hypothesised that placing posters containing social norm messages promoting vegetable consumption in three workplace restaurants, would increase the purchase of meals with vegetables, and that this effect would be sustained over time. The investigators recruited three restaurants to this study. For two weeks (Pre-intervention phase) the investigators used till receipts to monitor the number of meals sold with or without vegetables at baseline. For the following two weeks (Intervention phase) the investigators placed social norms posters around the three restaurants, while continuing to collect till receipts. After this, the posters were removed, and receipts were monitored for a final two weeks (Post-intervention).

Eligibility criteria: Inclusion Criteria:

* Purchase of a meal at one of the restaurants

Exclusion Criteria:

* None

Primary outcomes:
measure: Percentage of meals containing vegetables
timeFrame: 7 months
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United Kingdom
facility: University of Birmingham
state: West Midlands
Study officials:
affiliation: University of Birmingham
name: Jason M Thomas, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Thomas JM, Ursell A, Robinson EL, Aveyard P, Jebb SA, Herman CP, Higgs S. Using a descriptive social norm to increase vegetable selection in workplace restaurant settings. Health Psychol. 2017 Nov;36(11):1026-1033. doi: 10.1037/hea0000478. Epub 2017 May 25.
Clinical trial NCT01656863: Oral Rehydration Therapy in Children With Mild to Moderate Dehydration
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Parent
Attitudes
Keywords: Dehydration
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2012-08-03
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Parents of children suffering dehydration reporting to pediatric emergency room

Brief summary: The purpose of this study is to determine parental attitudes towards oral rehydration therapy for children with mild to moderate dehydration.


Eligibility criteria: Inclusion Criteria:

* Parents of dehydrated children aged 0-18

Exclusion Criteria:

* Child with severe dehydration
* Child with chronic disease causing dehydration

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Hadera
country: Israel
facility: Hillel Yaffe Medical Center
Study officials:
References:
Clinical trial NCT00780858: Premature Luteinization Prevention by GnRH Antagonist in Patients Undergoing IUI
Official title: GnRH Antagonist Prevention of Premature Luteinization in Patients Undergoing IUI
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infertility
Keywords: GnRH antagonist
IUI
Lead sponsor: IVI Madrid
Sponsor class: OTHER
First posted: 2008-10-28
Enrollment: 662
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy women with patent tubes who were undergoing IUI due to infertily of unknown origin.

Brief summary: Premature luteinization in patients undergoing IUI can occur in up to 24% of cycles. These patients, according to recent data, have a lower pregnancy rate than controls. The possibility to avoid premature luteinization with GnRH antagonist may restore the chances of achieving a pregnancy in these women.

Detailed description: The purpose of this study was to investigate whether a subset of patients benefits from GnRHa administration during IUI. PL was tested for in patients who were undergoing artificial insemination procedures, and the effect of GnRHa on PR in patients who

Eligibility criteria: Inclusion Criteria:

* previous failed IUI cycle with premature luteinization

Exclusion Criteria:

* 39 years or older
* not eligible for IUI (patent tubes, \> 3 million capacitated spermatozoa)
* 4 previous IUI cycles

Primary outcomes:
measure: Pregnancy rate
timeFrame: 2 weeks after intervention
Secondary outcomes:
measure: premature luteinization
timeFrame: at the time of intervention
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: IVI-Madrid
Study officials:
affiliation: IVI Madrid
name: Juan antonio García-Velasco, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kosmas IP, Tatsioni A, Kolibianakis EM, Verpoest W, Tournaye H, Van der Elst J, Devroey P. Effects and clinical significance of GnRH antagonist administration for IUI timing in FSH superovulated cycles: a meta-analysis. Fertil Steril. 2008 Aug;90(2):367-72. doi: 10.1016/j.fertnstert.2007.06.064. Epub 2007 Oct 23.
Clinical trial NCT02248558: Spurring Innovation to Promote HIV Testing: An RCT Evaluating Crowdsourcing
Official title: Crowdsourcing Versus Conventional HIV Testing Promotion: A Noninferiority Randomized Controlled Trial to Evaluate Promoting First-Time HIV Testing Among MSM and Transgender Individuals in China
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HIV
Keywords: Contest
Crowdsourcing
Innovation
Randomized controlled trial
China
Social entrepreneurship
Lead sponsor: University of North Carolina, Chapel Hill
Sponsor class: OTHER
Collaborators: name: Social Entrepreneurship to Spur Health
name: University of California, San Francisco
name: London School of Hygiene and Tropical Medicine
name: Guangdong Provincial Centers for Skin Diseases and STI Control
First posted: 2014-09-25
Enrollment: 721
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: Crowdsourcing may be a powerful tool to spur the development of innovative videos to promote HIV testing among key populations such as men who have sex with men (MSM) and transgender (TG) individuals. The purpose of this randomized controlled trial is to compare the effect of a crowdsourced video and a conventional video on first-time HIV testing among MSM and TG in China. The crowdsourced video was developed using an open contest, formal transparent judging, and an incentive of marketing promotion. The hypothesis is that a crowdsourced video will be equivalent (within a margin of 3%) to a conventional video in terms of self-reported first-time HIV testing within 3-4 weeks of watching the video.


Eligibility criteria: Inclusion Criteria:

* Born biologically male or identify as transgender
* 16 years or older
* Lifetime anal sex with another man
* Providing informed consent and active mobile phone number

Exclusion Criteria:

* HIV-infected
* HIV-tested ever in the past

Primary outcomes:
measure: First-Time HIV Testing
timeFrame: Up to 4 weeks following the video intervention
Secondary outcomes:
measure: Likelihood of HIV Testing
timeFrame: Up to one day
measure: Cost-effectiveness of Developing HIV Testing Promotional Videos
timeFrame: Up to one year
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: UNC Project-China
Study officials:
affiliation: UNC Project-China
name: Joseph Tucker
role: PRINCIPAL_INVESTIGATOR
References:
citation: Wang C, Mollan KR, Hudgens MG, Tucker JD, Zheng H, Tang W, Ling L. Generalisability of an online randomised controlled trial: an empirical analysis. J Epidemiol Community Health. 2018 Feb;72(2):173-178. doi: 10.1136/jech-2017-209976. Epub 2017 Nov 28.
citation: Tang W, Han L, Best J, Zhang Y, Mollan K, Kim J, Liu F, Hudgens M, Bayus B, Terris-Prestholt F, Galler S, Yang L, Peeling R, Volberding P, Ma B, Xu H, Yang B, Huang S, Fenton K, Wei C, Tucker JD. Crowdsourcing HIV Test Promotion Videos: A Noninferiority Randomized Controlled Trial in China. Clin Infect Dis. 2016 Jun 1;62(11):1436-1442. doi: 10.1093/cid/ciw171. Epub 2016 Apr 29.
Clinical trial NCT05900258: Tirbanibulin 1% Ointment for the Treatment of Chronically Sun-damaged Skin on the Face
Official title: Tirbanibulin 1% Ointment for the Treatment of Chronically Sun-damaged Skin on the Face
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Actinic Keratosis
Lead sponsor: Medical University of Graz
Sponsor class: OTHER
First posted: 2023-06-12
Enrollment: 22
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Interventional, monocentric, national, single-arm, uncontrolled, open, prospective phase IV study. Since this study is not powered for confirmative testing, analysis is done by descriptive statistics Eligible AK patients receive Tirbanibulin on sun-damaged areas of the face for five days, according to the SmPC. Diagnosis and monitoring of treatment effects are supported by UV imaging using Canfield VISIA®. Safety and efficacy are assessed at end of treatment visit (EoT, approximately 3 days after the last dose, i.e, day 8 ± 2) and at a follow-up visit (FuV) 57 ± 7 d after the start of the treatment. UV images (Canfield VISIA®) will be taken at baseline, EoT and FuV, accompanied by conventional dermatological assessment according to clinical routine.


Eligibility criteria: Inclusion Criteria:

* Informed consent
* Diagnosed with sun-damaged skin on the face and AK in the treatment area
* Willing and able to comply with all study procedures
* Use of medically acceptable contraception in males or females of child-bearing potential
* 51 -100 years of age
* Negative pregnancy test at baseline in females of childbearing potential

Exclusion Criteria:

* Allergy or intolerance towards the active ingredient or any of the constituents of the IMP
* Any contraindication for the IMP, according to the most recent version of the SmPC
* Open lesions of any kind on the face
* Concomitant cutaneous malignancy in treatment area, including but not restricted to squamous skin cancer
* Immune deficiency
* Participation in another clinical trial during the last six months
* Pregnancy or lactation

Primary outcomes:
measure: Unmasking of subclinical lesions in UV-exposed areas of chronically sun-damaged skin of the face by a treatment with Tirbanibulin.
timeFrame: 57± 7 days
Secondary outcomes:
Other outcomes:
Locations:
city: Graz
country: Austria
facility: Medizinische Universität Graz
Study officials:
References:
Clinical trial NCT01558258: A Mindfulness Meditation-Based Intervention for Younger Breast Cancer Survivors
Official title: A Mindfulness Meditation-Based Intervention for Younger Breast Cancer Survivors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Younger Breast Cancer Survivors
Lead sponsor: Jonsson Comprehensive Cancer Center
Sponsor class: OTHER
Collaborators: name: Susan G. Komen Breast Cancer Foundation
First posted: 2012-03-20
Enrollment: 71
Sex: FEMALE
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Younger women with breast cancer experience substantially greater distress and depressive symptoms than older women. These symptoms can hamper recovery and healthy behaviors that can reduce the risk of recurrence and/or other chronic diseases. The primary objective of this study is to evaluate the feasibility and preliminary efficacy of a mindfulness meditation-based intervention for this at-risk group of women. The investigators hypothesize that a structured program of mindfulness meditation will lead to significant improvements in psychological well-being (i.e., depression, stress), with corresponding improvements in health behaviors and biomarkers of cancer risk, in women diagnosed with breast cancer, prior to age 50. The investigators will also examine mechanisms for intervention effects, including increased mindfulness and ability to relax.


Eligibility criteria: Inclusion Criteria:

* women diagnosed with early, resectable breast cancer (Stage 0, I, II, or III) prior to age 50
* have completed treatment with surgery, radiation, and/or chemotherapy at least 3 months previously.

Exclusion Criteria:

* have a breast cancer recurrence, metastasis, or another cancer diagnosis (excluding non-melanoma skin cancer
* unable to commit to intervention schedule.

Primary outcomes:
measure: Effect of Mindful Awareness Practices on daily living.
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: UCLA
state: California
Study officials:
affiliation: Jonsson Comprehensive Cancer Center
name: Patricia Ganz, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04202458: Boosting REcanalization of Thrombectomy for Ischemic Stroke by Intra-arterial TNK (BRETIS-TNK)
Official title: Boosting REcanalization of Thrombectomy for Ischemic Stroke by Intra-arterial TNK (BRETIS-TNK): a Prospective, Random, Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Ischemic Stroke
Lead sponsor: General Hospital of Shenyang Military Region
Sponsor class: OTHER
First posted: 2019-12-17
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Thrombolysis and endovascular thrombectomy are the most efficient treatments for acute ischemic stroke patients in time window. However, sufficient recanalization (mTICI2b-3) can 't be acquired in all patients under thrombectomy. The EXTEND-IA TNK study indicated that tenecteplase before thrombectomy was associated with a higher incidence of reperfusion and better functional outcome than alteplase among patients with ischemic stroke treated within 4.5 hours after symptom onset. This study intends to explore whether a combination of thrombectomy and intra-arterial TNK administration can increase recanalization rate after the first attempt of thrombectomy device pass for ischemic Stroke.


Eligibility criteria: Inclusion Criteria:

1. Age ≥18 years;
2. Patients who presented with acute ischemic stroke and a large vessel occlusion in the anterior circulation and met the criteria of mechanical thrombectomy;
3. The subtype of ischemic stroke is large-artery atherosclerosis according to TOAST classification;
4. The availability of informed consent.

Exclusion Criteria:

1. Other sub-types of ischemic stroke such as cardioembolism.
2. Hemorrhagic stroke such as cerebral hemorrhage, subarachnoid hemorrhage.
3. Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia (\<100000/mm3).
4. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis.
5. Severe uncontrolled hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg).
6. Patients allergic to any ingredient of drugs in our study.
7. Unsuitable for this clinical studies assessed by researcher.

Primary outcomes:
measure: Proportion of sufficient recanalization
timeFrame: Immediately after TNK treatment
Secondary outcomes:
measure: Proportion of favorable outcome
timeFrame: 90 days
measure: proportion of early neurological improvement
timeFrame: 48 hours
Other outcomes:
measure: incidence of symptomatic intracranial haemorrhage
timeFrame: 48 hours
Locations:
city: ShenYang
country: China
facility: General Hospital of Northern Theater Command
Study officials:
References: